Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359280 | 0.99 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL5352722 | 0.96 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL5355716 | 0.91 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL25964543 | 0.86 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL3975752 | 0.86 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL5362597 | 0.86 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL5363190 | 0.85 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL3188702 | 0.85 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL3865999 | 0.85 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL3867904 | 0.85 | TLR7 (0.50) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | claimed |
| US-6667312-B2 | Useful as immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-23 | — | — | US | claimed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | claimed |
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-6949649-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| EP-1451191-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-6667312-B2 | Useful as immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-23 | — | — | US | disclosed |
| WO-2003050121-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209268-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.